Related Experiment Video
Updated: Aug 1, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Statistical issues in bioequivalence [correction of bioequivalance]
1Department of Epidemiology and Public Health, Department of Statistical Science, University College London, Gower Street, London WC1E 6BT, U.K. stephens@public-health.ucl.ac.uk
Statistics in Medicine
|August 28, 2001
Summary
Recent work on individual bioequivalence has sparked controversy. Clarifying the purpose of bioequivalence trials is crucial for establishing guidelines, which may ultimately prove unnecessary.
Area of Science:
- Pharmacokinetics and drug development
- Regulatory science
Background:
- Individual bioequivalence has been a recent focus, generating significant scientific and regulatory debate.
- Previous controversies surrounding average bioequivalence are reviewed to understand the current landscape.
Purpose of the Study:
- To examine the root causes of controversies in bioequivalence trial design and interpretation.
- To critically assess the fundamental purpose and necessity of bioequivalence studies.
Main Methods:
- Review of historical controversies in average bioequivalence.
- Analytical discussion of the objectives and interpretation of bioequivalence trials.
Main Results:
- Confusion regarding the primary goals of bioequivalence trials may have contributed to past controversies.
- The necessity and appropriate application of individual bioequivalence require further examination.
Conclusions:
- Clarification of the purpose of bioequivalence trials is essential before establishing guidelines for individual bioequivalence.
- Current guidelines for individual bioequivalence may need re-evaluation, potentially rendering them unnecessary.
More Related Videos
Related Concept Videos
01:16Bioequivalence: Overview
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
01:20Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...
01:15Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:16Bioequivalence Data: Statistical Interpretation
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...